PRPH - ProPhase Labs Inc Stock Price, Fair Value and News

5.28USD+0.09 (+1.73%)Market Closed

Market Summary

USD5.28+0.09

Market Closed

1.73%

PRPH Stock Price

View Fullscreen

PRPH RSI Chart

PRPH Valuation

Market Cap

95.3M

Price/Earnings (Trailing)

-5.68

Price/Sales (Trailing)

2.15

EV/EBITDA

-6.33

Price/Free Cashflow

-8.4

PRPH Price/Sales (Trailing)

PRPH Profitability

EBT Margin

-51.37%

Return on Equity

-33.98%

Return on Assets

-18.26%

Free Cashflow Yield

-11.91%

PRPH Fundamentals

PRPH Revenue

Revenue (TTM)

44.4M

Rev. Growth (Yr)

-83.97%

Rev. Growth (Qtr)

-58.17%

PRPH Earnings

Earnings (TTM)

-16.8M

Earnings Growth (Yr)

-257.99%

Earnings Growth (Qtr)

-70.22%

Breaking Down PRPH Revenue

Last 7 days

6.7%

Last 30 days

-23.4%

Last 90 days

3.9%

Trailing 12 Months

-42.2%

How does PRPH drawdown profile look like?

PRPH Financial Health

Current Ratio

2.28

Debt/Equity

0.06

Debt/Cashflow

-3.88

PRPH Investor Care

Shares Dilution (1Y)

10.86%

Diluted EPS (TTM)

-0.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	94.4M	78.5M	62.7M	44.4M
2022	87.8M	105.2M	113.9M	122.6M
2021	27.9M	33.4M	39.0M	79.0M
2020	9.4M	11.4M	12.5M	14.5M
2019	12.0M	10.5M	10.8M	9.9M
2018	12.5M	13.8M	13.2M	13.1M
2017	4.0M	4.8M	6.5M	9.9M
2016	15.8M	14.6M	11.6M	4.2M
2015	21.8M	22.2M	21.4M	20.6M
2014	23.7M	23.5M	22.7M	22.1M
2013	23.9M	24.0M	24.5M	25.0M
2012	20.3M	20.5M	20.8M	22.4M
2011	15.7M	16.3M	16.2M	17.5M
2010	0	18.0M	16.3M	14.5M
2009	0	0	0	19.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ProPhase Labs Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2023	karkus ted william	gifted	-	-	-50,000	ceo & chairman
Apr 05, 2023	karkus ted william	gifted	-	-	50,000	ceo & chairman
Apr 03, 2023	karkus ted william	gifted	-	-	-100,000	ceo & chairman
Feb 01, 2023	karkus ted william	sold (taxes)	-2,195,000	8.18	-268,337	ceo & chairman
Feb 01, 2023	karkus ted william	acquired	300,000	0.6	500,000	ceo & chairman
Jan 13, 2023	karkus ted william	sold (taxes)	-2,988,000	9.36	-319,231	ceo & chairman
Jan 13, 2023	karkus ted william	acquired	360,000	0.6	600,000	ceo & chairman
Oct 16, 2022	karkus ted william	sold (taxes)	-3,303,000	10.41	-317,291	ceo & chairman
Oct 16, 2022	karkus ted william	acquired	360,000	0.6	600,000	ceo & chairman
Aug 10, 2022	karkus ted william	sold (taxes)	-3,432,000	10.84	-316,605	ceo & chairman

Which funds bought or sold PRPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	unchanged	-	570	1,889	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	reduced	-7.27	24,000	96,000	-%
Apr 26, 2024	JAMISON PRIVATE WEALTH MANAGEMENT, INC.	new	-	-	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-87.77	-12,000	2,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-12.88	47,491	239,729	-%
Apr 24, 2024	Spire Wealth Management	new	-	518	518	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	added	6.74	-	1,000	-%
Apr 18, 2024	CHAPIN DAVIS, INC.	unchanged	-	78,000	258,800	0.10%
Mar 11, 2024	VANGUARD GROUP INC	added	1.25	124,208	2,754,250	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-14.94	-46,300	338,972	-%

Are Funds Buying or Selling PRPH?

Are funds buying PRPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRPH

No. of Funds

Unveiling ProPhase Labs Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 19, 2024	karkus ted william	20.3%	3,683,750	SC 13D/A
Apr 05, 2023	karkus ted william	20.9%	3,583,750	SC 13D/A
Apr 04, 2023	karkus ted william	20.9%	3,583,750	SC 13D/A
Feb 02, 2023	karkus ted william	21.6%	3,683,750	SC 13D/A
Jan 17, 2023	karkus ted william	22.8%	3,952,087	SC 13D/A
Oct 18, 2022	karkus ted william	24.9%	4,271,318	SC 13D/A
May 26, 2022	karkus ted william	27.3%	4,905,214	SC 13D/A
May 10, 2021	karkus ted william	28.8%	5,149,528	SC 13D/A
Aug 17, 2020	karkus ted william	34.7%	4,843,944	SC 13D/A
Mar 30, 2020	karkus ted william	33.6%	4,574,504	SC 13D/A

Recent SEC filings of ProPhase Labs Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 21, 2024	4/A	Insider Trading
Mar 19, 2024	SC 13D/A	13D - Major Acquisition
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to ProPhase Labs Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.8B	23.7B	0.37%	0.52%	41.54	7.7	-8.94%	-35.72%
A	40.3B	6.7B	-4.65%	2.00%	32.59	5.98	-2.81%	-6.58%
IDXX	39.3B	3.7B	-8.79%	-0.63%	45.35	10.55	8.57%	23.94%
DGX	15.1B	9.3B	3.07%	-0.16%	17.9	1.63	-3.29%	6.68%
MEDP	12.1B	2.0B	-0.37%	90.32%	38.77	6.17	25.57%	21.62%
CRL	11.8B	4.1B	-12.24%	20.01%	24.86	2.86	3.86%	-2.39%
NTRA	11.3B	1.1B	1.97%	79.75%	-26.03	10.45	31.99%	20.63%
EXAS	11.0B	2.5B	-17.90%	-4.95%	-53.83	4.4	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-14.08%	-28.73%	1.7K	2.9	28.93%	111.61%
GH	2.3B	563.9M	-10.63%	-19.43%	-4.72	4.01	25.45%	26.76%
SMALL-CAP
CDNA	480.0M	280.3M	-6.83%	8.80%	-2.52	1.71	-12.89%	-148.37%
ACRS	92.9M	31.2M	7.38%	-85.44%	-1.05	2.97	5.03%	-1.81%
APDN	69.4M	9.0M	851.16%	297.09%	-9.61	7.72	-53.31%	2.21%
AWH	39.6M	9.2M	17.15%	-34.36%	-2.37	4.33	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

ProPhase Labs Inc News

Latest updates

ProPhase Labs Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-58.2%	3,499	8,365	13,217	19,303	21,824	24,200	29,092	47,531	46,344	45,157	9,472	9,142	15,271	5,163	3,840	3,623	1,888	3,141	2,766	1,651	2,318
Gross Profit	-231.3%	-3,056	2,327	6,448	10,520	11,284	11,973	18,720	28,677	-	24,618	3,977	4,466	8,927	1,870	1,042	1,279	415	1,000	834	261	520
Operating Expenses	-5.8%	8,296	8,805	11,106	9,645	16,374	10,020	8,133	12,531	-	10,941	7,624	5,916	7,706	4,523	1,609	1,220	1,227	1,466	1,295	1,529	1,564
S&GA Expenses	-2.7%	8,022	8,245	9,937	8,298	12,743	7,512	6,306	7,824	-	7,780	5,938	4,993	3,782	3,623	1,552	1,155	1,168	132	302	342	266
R&D Expenses	-36.0%	274	428	572	144	479	110	28.00	35.00	-	104	208	93.00	115	452	57.00	65.00	59.00	86.00	57.00	95.00	94.00
EBITDA Margin	-114.3%	-0.34*	-0.16*	-0.03*	0.14*	0.23*	0.38*	0.36*	0.26*	0.11*	0.12*	0.03*	0.00*	-0.03*	-	-	-	-	-	-	-	-
Interest Expenses	79.6%	494	275	291	215	129	201	201	233	-	278	296	323	251	254	41.00	-	-	-	-	-	-
Income Taxes	-77.3%	-2,914	-1,644	-1,474	14.00	-2,745	809	2,965	3,416	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-71.9%	-11,665	-6,785	-4,914	564	-5,189	1,777	10,411	15,910	-	9,621	-3,978	-1,395	1,057	-	-	-	-	-	-	-	-
EBT Margin	-97.3%	-0.51*	-0.26*	-0.10*	0.08*	0.19*	0.33*	0.30*	0.21*	0.06*	0.07*	-0.06*	-0.07*	-0.08*	-	-	-	-	-	-	-	-
Net Income	-70.2%	-8,751	-5,141	-3,440	550	-2,444	968	7,446	12,494	-	10,589	-3,978	-1,395	1,057	-978	-408	70.00	-809	-467	-428	-1,238	-1,013
Net Income Margin	-126.3%	-0.38*	-0.17*	-0.06*	0.07*	0.15*	0.28*	0.25*	0.18*	0.07*	0.08*	-0.14*	-0.05*	-0.01*	-	-	-	-	-	-	-	-
Free Cashflow	94.9%	-238	-4,679	-6,982	451	786	2,607	4,796	20,262	-4,672	-4,672	-5,547	4,417	-7,917	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.2%	92.00	92.00	91.00	95.00	88.00	98.00	98.00	100	89.00	73.00	76.00	85.00	31.00	23.00	12.00	12.00	12.00	16.00	16.00	17.00	21.00
Current Assets	-4.4%	48.00	50.00	55.00	61.00	61.00	70.00	70.00	73.00	61.00	44.00	58.00	67.00	16.00	18.00	10.00	10.00	10.00	13.00	13.00	14.00	18.00
Cash Equivalents	129.2%	2.00	1.00	4.00	10.00	9.00	23.00	24.00	26.00	9.00	9.00	18.00	33.00	7.00	11.00	3.00	1.00	0.00	1.00	1.00	2.00	2.00
Inventory	-24.0%	4.00	5.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	9.00	15.00	16.00	3.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	2.00
Net PPE	-100.0%	-	13.00	9.00	9.00	7.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Goodwill	0%	5.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-
Liabilities	20.6%	43.00	35.00	32.00	35.00	24.00	30.00	30.00	33.00	31.00	24.00	29.00	33.00	21.00	12.00	1.00	1.00	1.00	1.00	1.00	-	4.00
Current Liabilities	27.1%	21.00	16.00	14.00	18.00	16.00	17.00	17.00	20.00	16.00	10.00	14.00	18.00	6.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	4.00
Long Term Debt	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-12.5%	49.00	56.00	59.00	60.00	64.00	68.00	68.00	66.00	59.00	48.00	48.00	53.00	11.00	11.00	11.00	11.00	11.00	14.00	15.00	16.00	17.00
Retained Earnings	-235.1%	-5.03	4.00	9.00	12.00	12.00	14.00	13.00	10.00	3.00	-7.95	-3.97	-2.57	-3.63	-2.65	-2.24	-2.31	-1.51	2.00	2.00	4.00	5.00
Additional Paid-In Capital	0.5%	119	118	114	111	109	108	106	106	105	104	99.00	103	62.00	61.00	61.00	60.00	60.00	60.00	60.00	60.00	59.00
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Shares Outstanding	0%	18.00	18.00	17.00	17.00	16.00	16.00	16.00	15.00	15.00	16.00	-	15.00	12.00	12.00	-	-	-	-	-	-	-
Float	-	-	-	100	-	-	-	152	-	-	-	73.00	-	-	-	13.00	-	-	-	19.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	95.4%	-213	-4,654	-6,957	476	811	2,632	4,821	20,287	-4,647	-5,522	4,442	-7,892	-6,768	-481	4,372	285	-428	-889	-927	1,403	-781
Share Based Compensation	-21.1%	676	857	1,056	947	1,007	1,969	528	482	745	934	1,076	428	780	283	198	198	188	180	180	196	201
Cashflow From Investing	-480.7%	-1,264	332	1,215	-1,652	-5,003	-670	-488	4,084	5,484	-3,372	-14,946	-6,832	2,658	-1,120	-2,532	-22.00	2,787	808	-474	2,422	66.00
Cashflow From Financing	143.7%	2,924	1,200	-47.00	1,680	-9,498	-3,122	-6,181	-7,222	-962	-	-4,546	40,635	66.00	-	-	-	-2,893	-	-	-2,929	-
Dividend Payments	-	-	-	-	-	2.00	-	4,705	4,646	-	-	-	-	-	-	-	-	2,893	-	-	2,929	-
Buy Backs	-	-	-	47.00	541	952	50.00	-	1,150	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PRPH Income Statement

2023-12-31

Consolidated Statements of Operations and Other Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues, net	$ 44,384	$ 122,647
Cost of revenues	28,145	51,993
Gross profit	16,239	70,654
Operating expenses:
Diagnostic expenses	1,932	12,022
General and administration	34,502	34,385
Research and development	1,418	652
Total operating expenses	37,852	47,059
(Loss) income from operations	(21,613)	23,595
Interest income, net	78	153
Interest expense	(1,275)	(764)
Change in fair value of investment securities	0	(76)
Other income	10	0
(Loss) income from operations before income taxes	(22,800)	22,908
Income tax benefit (expense)	6,018	(4,445)
Loss (income) from operations after income taxes	(16,782)	18,463
Other comprehensive (loss) income:
Unrealized gain on marketable debt securities, net of taxes	(1,057)	932
Total comprehensive (loss) income	$ (17,839)	$ 19,395
Earnings (loss) per share:
Basic (in dollars per share)	$ (0.98)	$ 1.17
Diluted (in dollars per share)	$ (0.98)	$ 1.02
Weighted average common shares outstanding:
Basic (in shares)	17,207	15,845
Diluted (in shares)	17,207	18,651

PRPH Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets, Current [Abstract]
Cash and cash equivalents	$ 1,609	$ 9,109
Restricted cash	540	0
Marketable securities, available for sale	3,127	8,328
Accounts receivable, net	36,313	37,054
Inventory, net	3,841	3,976
Prepaid expenses and other current assets	2,155	2,366
Total current assets	47,585	60,833
Property, plant and equipment, net	12,898	7,288
Prepaid expenses, net of current portion	832	121
Operating lease right-of-use asset, net	4,572	4,059
Intangible assets, net	12,333	8,475
Goodwill	5,231	5,709
Deferred tax asset	7,313	0
Other assets	1,163	1,163
TOTAL ASSETS	91,927	87,648
Current liabilities
Accounts payable	9,383	5,905
Accrued diagnostic services	314	1,009
Accrued advertising and other allowances	24	99
Finance lease liabilities	1,840	0
Operating lease liabilities	953	301
Deferred revenue	2,382	2,499
Income tax payable	3,278	4,190
Other current liabilities	2,683	2,072
Total current liabilities	20,857	16,075
Non-current liabilities:
Long-term debt, net of discount of $341	2,924	0
Due to sellers (see Note 3)	2,000	0
Deferred revenue, net of current portion	1,100	1,059
Deferred tax liability, net	0	224
Finance lease liabilities, net of current portion	4,092	0
Operating lease liabilities, net of current portion	4,237	4,259
Total non-current liabilities	21,687	7,942
Total liabilities	42,544	24,017
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	91,927	87,648
COMMITMENTS AND CONTINGENCIES
Stockholders’ equity
Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding	0	0
Common stock authorized 50,000,000, $0.0005 par value, 18,045,029 and 16,210,776 shares outstanding, respectively	18	16
Additional paid-in capital	118,694	109,138
Retained earnings (accumulated deficit)	(5,029)	11,753
Treasury stock, at cost, 18,940,967 and 18,126,790 shares, respectively	(64,000)	(58,033)
Accumulated other comprehensive loss	(300)	757
Total stockholders’ equity	49,383	63,631
2023 Note
Non-current liabilities:
Unsecured convertible promissory notes, net	7,334	0
September 2020 Notes
Non-current liabilities:
Unsecured convertible promissory notes, net	$ 0	$ 2,400

About ProPhase Labs Inc

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

CEO	Mr. Ted William Karkus
WEBSITE	prophaselabs.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	129

ProPhase Labs Inc Frequently Asked Questions

What is the ticker symbol for ProPhase Labs Inc? What does PRPH stand for in stocks?

PRPH is the stock ticker symbol of ProPhase Labs Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProPhase Labs Inc (PRPH)?

As of Thu May 02 2024, market cap of ProPhase Labs Inc is 95.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRPH stock?

You can check PRPH's fair value in chart for subscribers.

What is the fair value of PRPH stock?

You can check PRPH's fair value in chart for subscribers. The fair value of ProPhase Labs Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ProPhase Labs Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ProPhase Labs Inc a good stock to buy?

The fair value guage provides a quick view whether PRPH is over valued or under valued. Whether ProPhase Labs Inc is cheap or expensive depends on the assumptions which impact ProPhase Labs Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRPH.

What is ProPhase Labs Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, PRPH's PE ratio (Price to Earnings) is -5.68 and Price to Sales (PS) ratio is 2.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ProPhase Labs Inc's stock?

In the past 10 years, ProPhase Labs Inc has provided 0.176 (multiply by 100 for percentage) rate of return.